IFF Achieves EcoVadis Platinum Rating for Corporate Social Responsibility Leadership
IFF (NYSE:IFF) (TASE: IFF), a leading innovator of taste, scent, nutrition & ingredients, announced today that it has been awarded the 2020 EcoVadis platinum sustainability rating, a new and more highly selective designation introduced by the internationally recognized platform earlier this year.
As the leading solution for monitoring sustainability in global supply chains, EcoVadis rates and benchmarks the quality of a company's sustainability performance and management systems through an assessment in four areas: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. With an overall score of 73% for 2020 and noted strengths in Environment and Sustainable Procurement, the award puts IFF among the top 1% of companies assessed.
“IFF has been recognized in EcoVadis’ top performing category every year since 2014. As they now set the bar higher through more stringent criteria and the introduction of the Platinum category, IFF is thrilled to match the pace by continuing to strengthen our sustainability leadership position. While 2020 was a challenging year in many ways, sustainability remained a top priority for us and is an essential driver of our resiliency and success moving forward,” said IFF Chairman & CEO, Andreas Fibig.
The rating follows other recent accolades IFF has received for its sustainability performance. In addition to being named for the first time to the Dow Jones Sustainability Indices, IFF was named to “America’s Most Responsible Companies 2021” list by Newsweek for the second consecutive year. IFF ranked first out of 43 companies in the Materials industry and 18 out of 400 companies overall, up 17 spots from the inaugural listing of 300 companies last year. Results were derived from publicly available key performance indicators, as well as an independent survey of U.S. citizens.
IFF has also been recognized by global environmental non-profit CDP, securing a place for the third consecutive year on its prestigious ‘A List’ for tackling water security. CDP’s annual environmental disclosure and scoring process is widely recognized as the gold standard of corporate environmental transparency, and IFF is one of a small number of high-performing companies out of 5,800+ that were scored. Through significant demonstrable action to protect water resources, IFF is leading on corporate environmental ambition, action and transparency worldwide.
For more on IFF’s commitment to sustainability, visit www.iff.com/sustain .
Welcome to IFF
At IFF (NYSE:IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TX-GPD-COMPANIES22.1.2021 14:35:10 CET | Press release
GPD Companies, Inc. to Acquire Distrupol
TX-SCHLUMBERGER22.1.2021 12:52:04 CET | Press release
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results
CA-ANDERSEN-GLOBAL22.1.2021 11:04:11 CET | Pressemeddelelse
Andersen Global styrker sin afrikanske platform med Kashadah & Co.
JEOL22.1.2021 07:02:12 CET | Press release
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)
DAWEX/NUMALIM/ORANGE22.1.2021 01:58:07 CET | Press release
NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform
VIIV-HEALTHCARE21.1.2021 23:14:12 CET | Press release
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
DE-INCYTE21.1.2021 22:32:11 CET | Press release
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom